Celcuity Inc. (CELC) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Salcuity (CELC) Q1 2026: $2.5B Peak Revenue Target as Getatelicib Launch Nears Approval
  May 15, 2026
• Selcuity (CELC) Q4 2025: R&D Spend Climbs 40% as Getatilicib Nears $5B Market Opportunity
  March 26, 2026
• Salcuity (CELC) Q3 2025: $287M Capital Raise Fuels Getatolisib Launch Ambitions
  November 13, 2025
• Cellcuity (CELC) Q2 2025: $287M Capital Raise Extends Runway for Potential $5B Breast Cancer Launch
  August 14, 2025
• Cellcuity (CELC) Q1 2025: R&D Spend Jumps 56% as Pivotal Victoria 1 Data Nears
  July 03, 2025

Browse all companies